Cilag AG

DUBLIN, May 11, 2023 /PRNewswire/ -- The "Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2016-2023" report has been added to ResearchAndMarkets.com's offering. The Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2016-2023 report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in cancer monoclonal antibody partnering deals Most active companies in cancer monoclonal antibody partnering Disclosed headlines, upfronts, milestones and royalties by stage of development Cancer monoclonal antibody partnering contract documents Top cancer monoclonal antibody deals by value This report provides details of the latest cancer monoclonal antibody agreements announced in the healthcare sectors. This report provides details of the latest antibody agreements announced in the healthcare sectors, covering: Monoclonal antibodies Murine mAb Chimeric mAb Humanized mAb Human aAb Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not. This report contains a comprehensive listing of all cancer monoclonal antibody partnering deals announced since Jan 2016, including financial terms where available, including links to online deal records of actual cancer monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. The initial chapters of this report provide an orientation of cancer monoclonal antibody dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in cancer monoclonal antibody dealmaking since 2016, including details of average headline, upfront, milestone and royalty terms. Chapter 3 provides a review of the leading cancer monoclonal antibody deals since 2016. Deals are listed by headline value, signed by big pharma, most active cancer monoclonal antibody dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 4 provides a comprehensive listing of the top 25 most active companies in cancer monoclonal antibody dealmaking with a brief summary followed by a comprehensive listing of cancer monoclonal antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. Chapter 5 provides a comprehensive and detailed review of cancer monoclonal antibody partnering deals signed and announced since Jan 2016, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Chapter 6 provides a comprehensive and detailed review of cancer monoclonal antibody partnering deals signed and announced since Jan 2016. The chapter is organized by specific cancer monoclonal antibody technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. In addition, a comprehensive appendix is provided organized by cancer monoclonal antibody partnering company A-Z, deal type definitions and cancer monoclonal antibody partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in cancer monoclonal antibody partnering and dealmaking since 2016. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of cancer monoclonal antibody technologies and products. Key benefits Global Cancer Monoclonal Antibody Partnering Terms & Agreements provides the reader with the following key benefits: In-depth understanding of cancer monoclonal antibody deal trends since 2016 Access to headline, upfront, milestone and royalty data Comprehensive access to over 600 actual cancer monoclonal antibody deals entered into by the world's biopharma companies Identify most active companies in cancer monoclonal antibody partnering Insight into the terms included in a cancer monoclonal antibody agreement Understand the key deal terms companies have agreed in previous deals Undertake due diligence to assess suitability of your proposed deal terms for partner companies Spot the emerging companies in the cancer monoclonal antibody area Report scope Global Cancer Monoclonal Antibody Partnering Terms & Agreements is intended to provide the reader with an in-depth understanding and access to cancer monoclonal antibody trends and structure of deals entered into by leading companies worldwide. Cancer Monoclonal Antibody Partnering Terms & Agreements includes: Trends in cancer monoclonal antibody dealmaking in the biopharma industry since 2016 Access to headline, upfront, milestone and royalty data Access to over 600 cancer monoclonal antibody deal records The leading cancer monoclonal antibody deals by value since 2016 In Cancer Monoclonal Antibody Partnering Terms & Agreements, the available deals are listed by: Company A-Z Headline value Stage of development at signing Deal component type Specific oncology therapy target Monoclonal antibody type Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The Cancer Monoclonal Antibody Partnering Terms & Agreements report provides comprehensive access to available deals and contract documents for over 600 cancer monoclonal antibody deals. Analyzing actual contract agreements allows assessment of the following: What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Companies Mentioned 3SBio Abpro Ambrx Amgen ATP Bayer Binex Biomm Cipla Dako Eisai I-mab IMV Ipsen IRBM Kymab Lonza Merus MSD Numab Roche Taiho UCB VIB Wilex Xoma Cilag AG NKMax America Viela Bio Essex Bio-Technology For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

Noah Medical is currently the defendant in a lawsuit lodged by Johnson & Johnson’s robotic surgery subsidiaries Auris Health and Verb Surgical, which accuses three former Auris employees of taking trade secrets to Noah. Just weeks after securing an FDA clearance for its robotic lung surgery system, Noah Medical has been flooded with venture capital dollars. The Silicon Valley-based company raised $150 million to help build a commercial engine behind its Galaxy system, designed to perform navigated lung bronchoscopies using disposable probes. Noah’s series B round was led by the Softbank Vision Fund and co-led by Prosperity7 Ventures. Additional backers included Tiger Global, Hillhouse, Sequoia China, Shangbay Capital, Uphonest Capital, Sunmed Capital, Lyfe Capital, 1955 Capital and AME Cloud Ventures plus other undisclosed investors. The FDA’s clearance of the Galaxy system was announced in early March. With a small, cart-based robotic arm, the platform snakes a bronchoscope through the airways of the lung to get a closer look at suspicious tissue nodules that may harbor any developing cancer cells. With single-use, replaceable hardware, the company says its approach allows for faster turnaround times between patients—by doing away with cleaning and reprocessing steps—and reduces the risks of cross-contamination. The system is also equipped with what Noah has dubbed Tool-in-Lesion Tomo+ technology, or TiLT+, which provides surgeons with real-time, image-guided updates to help confirm when the biopsy tool is fully within its target tissue. “Next generation robotics platforms like the Galaxy System are filling procedural gaps to provide superior clinical values to better serve customers’ needs,” Noah founder and CEO Jian Zhang said in a release. The company has also launched first-in-human clinical trials at Macquarie University Hospital in Sydney. But the deluge of cash may cause some consternation among Noah’s competitors. The company is currently the defendant in a lawsuit lodged by Johnson & Johnson’s robotic surgery subsidiaries—Auris Health and Verb Surgical, plus its Cilag pharmaceutical unit—that accuses three former Auris employees of transferring trade secrets to Noah. J&J’s complaint claims one of Noah’s patent applications includes Auris tech and was filed within weeks of a former employee joining the company; another application depicts a Noah catheter that J&J said is “indistinguishable from a figure in a confidential Auris presentation from February 2015.” Earlier this month, the judge overseeing the case in Northern California’s federal court denied a move from Noah to have the dispute resolved through arbitration. The court has scheduled a hearing on Noah’s motion to dismiss Auris’ complaints for May 10.

DUBLIN, April 4, 2023 /PRNewswire/ -- The "Global Cardiovascular Partnering 2016-2023: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering. Global Cardiovascular Partnering 2016 to 2023 provides the full collection of cardiovascular disease deals signed between the world's pharmaceutical and biotechnology companies since 2016. Trends in cardiovascular partnering deals Financial deal terms for headline, upfront and royalty by stage of development Cardiovascular partnering agreement structure Cardiovascular partnering contract documents Top cardiovascular deals by value Most active cardiovascular dealmakers Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element. The report takes readers through the comprehensive cardiovascular disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering cardiovascular deals. The report presents financial deal terms values for cardiovascular deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals. The initial chapters of this report provide an orientation of cardiovascular dealmaking trends. Chapter 1 provides an introduction to the report. Chapter 2 provides an overview of the trends in cardiovascular dealmaking since 2016 covering trends by year, deal type, stage of development, technology type and therapeutic indication. Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates. Chapter 4 provides a review of the leading cardiovascular deals since 2016. Deals are listed by headline value. The chapter includes the top 25 most active cardiovascular dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 5 provides comprehensive access to cardiovascular deals since 2016 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand. Chapter 6 provides a comprehensive directory of all cardiovascular partnering deals by specific cardiovascular target announced since 2016. The chapter is organized by specific cardiovascular therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. In addition, a comprehensive appendix is provided with each report of all cardiovascular partnering deals signed and announced since 2016. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in cardiovascular partnering and dealmaking since 2016. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of cardiovascular technologies and products. Report scope Global Cardiovascular Partnering 2016-2023: Deal trends, players and financials is intended to provide the reader with an in-depth understanding and access to cardiovascular trends and structure of deals entered into by leading companies worldwide. Global Cardiovascular Partnering 2016-2023: Deal trends, players and financials includes: Trends in cardiovascular dealmaking in the biopharma industry since 2016 Access to headline, upfront, milestone and royalty data Access to over 850 cardiovascular deal records The leading cardiovascular deals by value since 2016 The report includes deals for the following indications: Abdominal aortic aneurysm, Angina, Arrhythmia, Atrial fibrillation, Long QT syndrome, Supraventricular Tachycardia, Ventricular fibrillation, Ventricular tachycardia, Atherosclerosis, Breathlessness, Cardiogenic shock, Cardiomyopathy (heart muscle disease), Chest pain, Congenital heart disease, Congestive heart failure, Coronary artery disease, Ductus arteriosus, Fatigue, Hypercholesterolemia, Hypertension, Intermittent claudication, Ischemic heart disease, Limb ischemia, Marfan's Syndrome, Myocardial Infarction, Oedema (excess fluid), Palpitations, Peripheral arterial disease, Thrombus (blood clot), Valvular heart disease, Aortic stenosis, Restenosis, Varicose veins, plus other cardiovascular indications. In Global Cardiovascular Partnering 2016-2023: Deal trends, players and financials, the available deals are listed by: Company A-Z Headline value Stage of development at signing Deal component type Specific therapy target Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The Global Cardiovascular Partnering 2016-2023: Deal trends, players and financials report provides comprehensive access to available deals and contract documents for over 850 cardiovascular deals. Analyzing actual contract agreements allows assessment of the following: What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are the sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Selection of Companies Mentioned 1A Pharma 3PrimeDx 4D Molecular Therapeutics 4D Pharma 4SC Discovery 36 Strategies General Trading 480 Biomedical A&D Medical A&E Medical A*STAR Agency for Science Technology and Research AADi Abbott Laboratories Abbott Vascular Devices Abiomed Ab Medica Abyrx Acasti Pharma Accenture Access Scientific Access Vascular ACEA Biosciences Acino Pharma Actelion Actuated Cardio Engineering Actuated Medical Acutus Medical ADAS 3D Medical AddUp Admedus Admera Health Advanced BioScience Laboratories Advanced Cardiac Therapeutics Advanced Catheter Therapies Advanced Cooling Therapy Adventus Ventures Aegerion Pharmaceutical Aerolase Agena Bioscience Agilent Technologies Akcea Therapeutics Akers Biosciences Akrimax Pharmaceutical Akums Drugs and Pharmaceuticals Alibaba Health AliveCor Allegiance Health Foundation Allergan Alliance Medical Alnylam Pharmaceuticals Altrix Medical Amarin Amarna Therapeutics American College of Emergency Physicians American College of Physicians Foundation American College of Surgeons American Heart/Stroke Association American Heart Association AmeriCares Amgen Amneal Pharmaceuticals AmorChem Amos Gazit AnaBios Analog Devices AnaMar Angel Medical Systems AnGes MG Angiodynamics Angion Biomedica Angionetics AngioSoma ANI Pharmaceuticals Antares Pharma Antaros Medical Anthem Anthos Therapeutics AOP Orphan Pharmaceuticals APAC Scientific Apicore Aplagon Apollo Hospitals Group Apotex Apple Applied Medical Aptahem Aralez Pharmaceuticals Ardelyx Arena Pharmaceuticals argenx Argon Medical Devices Armetheon Aronora Arrowhead Pharmaceuticals Arteriae Arterial Health International Arterial Remodeling Technologies Asahi Intecc Ashland-Boyd County Health Department ASKA Pharmaceuticals Aspen Global Aspen Holding Aspire Health Science Astellas Pharma AstraZeneca AstraZeneca HealthCare Foundation Atelerix Athersys Atnahs Pharma AutoGenomics Autotelic Aviir Diagnostics Awamedica Axiogenesis Axol Bioscience Aziyo Biologics Baker IDI Heart and Diabetes Institute Bardy Diagnostics Baxter International Bayer Bayer Healthcare Bay Labs B Braun Beijing Leadman Biochemistry Beijing SL Pharma Bellerophon Therapeutics Bened Biomedical Berg Bertin Pharma Bicycle Therapeutics Bina Technologies BioCardia Bioengineering Laboratories Biofourmis BioHeart BioLamina BIOLIFE4D BioLife Solutions Biomerics BioSig Technologies Biostar Biostar Pharmaceuticals Biotectix BioTelemetry Biotricity Biotronik BioVectra Bioventix Biovic Sdn bhd Bird Foundation BlueRock Therapeutics BodyTrace Boehringer Ingelheim Boryung Pharmaceutical Boston Medical Center Boston Pharmaceuticals Boston Scientific Breckenridge Pharmaceuticals Brigham and Women's Hospital Brigham Young University Bristol-Myers Squibb Broad Institute Brooks Automation Burgerhospital Cadila Pharmaceuticals Caladrius Biosciences California Institute for Regenerative Medicine California Institute of Technology Canadian Institutes of Health Research Capellabio Capricor Therapeutics Caprion Proteomics Cardiac Insight Cardiac Life Cardinal Health CardiNor Cardio3 Biosciences Asia Holdings CardioDx CardioFocus CardioLogic Cardiome Pharma Cardiorentis Cardiovascular Cell Therapy Research Network Cardiovascular Research Foundation Cardiovascular Systems Cardiowise Cardium Therapeutics Cardurion Pharmaceuticals CareDx CareLearning Carestream Health CareTaker Medical Carmat Carmel Pharma Carrum Health Casebia Therapeutics Case Western Reserve University CASI Pharmaceuticals CAS Medical Systems Catherine's Health Center Catheter Precision CDC Foundation Cedars-Sinai Health System Cedars-Sinai Medical Center Celgene Celladon Cell and Gene Therapy Catapult CELLINK CellProThera Cell Therapy Celltrion Cellular Logistics CeloNova BioSciences Celyad Center for Biomarker Research in Medicine Center for Connected Health Centers for Medicare and Medicaid Services Centron Diagnostics Cevec Pharmaceuticals Chameleon BioSurfaces Charles River Laboratories Chek Diagnostics Chiesi Farmaceutici Children's Heart Foundation Children's Hospital Boston Children's Hospital of Philadelphia Children's Medical Research Institute Children's Hospital Oakland Research Institute (CHORI) China Grand Pharmaceutical China Medical System Chinese Future Industry Investment Fund Chinese Society of Cardiology Chong Kun Dang Christiana Care Health System Cilag AG C Illies CinCor Pharma Cipher Pharmaceuticals Cipla Medpro Citius Pharmaceuticals Clarity Pharmaceuticals ClearFlow Cleveland Clinic Cleveland HeartLab Clinlogix Coeptis Pharmaceuticals Cofactor Genomics Colibri Heart Valve College of Life Science of Northwest University Columbia University Medical Center Conavi Medical Concordia Healthcare Contatti Medical Cook Medical Coqui RadioPharmaceuticals Cordis CorDynamics CoreRx Pharma Corindus Vascular Robotics CorMatrix Cardiovascular Coroneo CorpMedical Correvio CorVascular Corvia Medical Corvida Medical Corvidia Therapeutics Covalon Technologies Covance Covidien Covis Pharmaceutical Cranford Pharmaceuticals CRISPR Therapeutics Critical Diagnostics Crown Bioscience Cryolife CSL Cure Duchenne CVie CyberHeart Cyclenium Pharma Cynata Therapeutics Cytori Therapeutics CytoSorbents Daewoong Pharmaceutical Daiichi Sankyo DalCor Pharmaceuticals Dalhousie University Dassault Systems DaVinci Biomedical Research Products DecImmune Therapeutics deCODE Genetics Delta Deltex Medical Denovo Biopharma Department of Defense Department of Health and Human Services Dewpoint Therapeutics Diablo Clinical Research diaDexus DiA Imaging Analysis Diaxonhit Dicerna Pharmaceuticals DiNAQOR Dizal Pharmaceutical Dogma Therapeutics Domainex Dorizoe Lifesciences Dr. Reddy's Laboratories Drukier Institute for Children's Health DSM Duke-NUS Graduate Medical School Singapore Duke Clinical Research Institute (DCRI) Duke University Duke University Medical Center Eagle Pharmaceuticals EB Neuro eCardio Diagnostics Eddingpharm Edwards Lifesciences Eiger BioPharmaceuticals Eko ELC Group Electrical Geodesics Elexopharm Eli Lilly Elkhorn Logan Valley Public Health Department Embolitech EmboMedics Emory University Enamine Endo International Endologix Endospan Endotronix Enterprise Partners Venture Capital ENYO Pharma Epsilon Erasmus University Medical Center ERS Genomics ERT Esaote Esperion Therapeutics Espero Pharmaceuticals Eurolab Especialidades Medicinales de Eurofar European Commission European Innovation Council Event Cardio Group Everest Medicines Excelera Network Exelixis Expression Analysis ExScientia FABPulous Feinstein Institute for Medical Research FEops FibriCheck Fine Foods & Pharmaceuticals N.T.M. First Check Diagnostics FitBit Food and Drug Administration (FDA) Foundation for Community Partnerships Frankfurt University Hospital FSD Pharma Fujifilm Fujifilm medical systems Fundacion Progreso y Salud Fu Wai Hospital G3 Pharmaceuticals Galenicum Health Gardia Medical For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets